SMA stem-cell 'success' claims are scarce due to minimal data. The few case series describe 'stabilisation' in individual children; no controlled trial has set a consensus rate. Approved therapies (nusinersen, gene therapy) show proven motor and survival benefit in controlled trials; stem cells are not proven to match them. Any benefit, if real, would be slowing of decline — evidence is insufficient for strong claims.
Five registered trials and 1 recruiting study address stem-cell therapy in SMA — the smallest landscape among the conditions here. Published data are sparse and largely single-centre observational. Some describe stabilisation or slowed decline over 6–12 months; others minimal change. SMA's rapid natural progression makes any stability potentially notable, but separating stem-cell effects from approved disease-modifying therapies (nusinersen, gene therapy) is difficult without controls. No trial has reversed motor-neuron loss.
Sunt un candidat? → · Spinal Muscular Atrophy: full overview → · Cost Atrofie Musculară Spinală → · Cost →
Revizuit medical de echipa editorială a StemCellAtlas cu Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită